

Dear Colleagues and Friends,

I am proud to announce my application for the future chair vacancy of the Chronic Malignancies Working Party (CMWP) in 2026. I am currently Professor of Haematology in Saint-Louis Hospital in Paris, France, where I work in the Bone Marrow Transplant department (CIC 207). From 2003, I was honoured to be taught by Professor Eliane Gluckman, one of the first leader-pioneers in the field, and then by Professor Gérard Socié at clinical, research and education levels.

After a Master in Blood Cells, I obtained a PhD on immune responses in myeloid malignancies at the University Paris-Cité in Christine Chomienne's research laboratory. In my institution, I am in charge of the pre- or post-transplantation management of patients, especially but not only patients suffering from MPN and MDS. I am also responsible for JACIE at my institution, which brings together six departments of haematology involved in CART-cells, autologous and allogeneic transplantations. Our hospital has been actively participating in the EBMT registry from the very start. We continue to implement the registry with around 100 autologous transplants, 150 CAR T-cells and 150 allogeneic transplantations every year.

I have worldwide experience, beginning with an internship at MD Anderson (Houston, United States) in 1998 while I was a medical student. I also spent a sabbatical year at Kings College London in 2015/2016, which fostered my knowledge in the MDS field.

Regarding the CMWP, I've been deeply involved in the last 15 years, with a first paper on behalf of the group published in 2011 and many others afterwards. In our group, I have always tried to promote research through many retrospective studies. I have also organized many meetings in Paris (2012, 2017, 2019) and elsewhere. One of the most important tasks I have achieved was to introduce new young haematologists to our field and to facilitate collaboration between centres. I have been honoured to be chosen by Nicolaus Kroger to lead the sub-chair MDS position, and to be renewed by the next chairs Ibrahim Yakoub-Agha and Donal Mc Lornan who trust me again in this role. I learned a lot during that time and I want to share this unique experience with the youngest ones, who are the future of our group.

In addition, I've been President of the French speaking Society of Cellular Therapy for the last four years, facilitating the relationships between EBMT and our French community, especially for all registry or legal issues. In addition to clinical and biological studies, and many scientific meeting organizations, I also had to manage administrative and financial issues of the French Society, which gives me some background for a further position at the EBMT.

Concerning clinical research, I designed, set up and coordinated several national academic prospective clinical trials on MDS and myelofibrosis. I obtained several grants to safely conduct those studies. The main achievements concern donor availability in

higher risk MDS patients (Leukemia 2015), a phase 2 trial on ruxolitinib before transplantation in myelofibrosis (BMT 2021), a phase 2 study maintenance by decitabine cedazuridine (Lancet Haematology 2025), the identification of biomarkers in GVHD (Blood Advances 2022), as well as haplo-identical transplantation in myelofibrosis (oral presentation at ASH 2025).

As a chair, I would like to promote biological and prospective clinical studies. I will ensure small centres and young colleagues will be looked upon to be promoted and will participate in our activities. I think that collaborative studies can be productive for their additional value, in terms of data and fruitful discussions. Another point which is important to me is the relationship with patients and their family. I initiated shared meetings during my French presidency, which was tremendously important to foster constructive collaborations between advocacy groups and expert physicians.

For all these reasons, I am fully motivated and dedicated to endorsing the chair position of the CMWP. I would be honoured to have your trust and support to contribute to the excellence of our EBMT group worldwide. With more than 15 years of experience within the CMWP and 23 years in the transplantation field, I have had the privilege to be taught by renowned colleagues. I have a deep desire to share my knowledge and experience for the four coming years and to serve you as a chair.

Professor Marie Robin, MD, PhD
Hôpital Saint-Louis, Université Paris Cité
Paris, France